CD274 and neoplasm: In contrast to the expression of PD-L1, a detailed retrospective biomarker analysis of patients enrolled in the CheckMate 032 trial suggested improved ORR, OS, and PFS of nivolumab monotherapy or nivolumab plus ipilimumab combination therapy in patients with a high tumor mutation burden (TMB) relative to patients with a low/medium TMB (64).